Last updated: February 15, 2026
Product Overview
NDC 00002-3229 corresponds to Remicade (infliximab), a monoclonal antibody used primarily for autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and psoriasis. Since its approval in 1998, Remicade has maintained a substantial market presence due to its efficacy and branded status.
Market Landscape
- The global biologics market for autoimmune diseases is expanding at an average annual growth rate (CAGR) of approximately 8% as of 2022.
- The U.S. autoimmune biologics market alone is estimated at over $30 billion in 2022, with infliximab representing a significant share.
Competitive Environment
- Biosimilar infliximab products have entered the market, including products from Pfizer (Inflectra/Remsima), Samsung Bioepis, and others.
- The biosimilar market share for infliximab in the U.S. reached about 35% in 2022, with biosimilars capturing faster adoption outside of the U.S. due to regulatory and pricing barriers.
Pricing Trends
- Branded Remicade's list price in the U.S. ranged between $2,700 and $3,200 per infusion, depending on the dose and treatment duration.
- Biosimilars are priced approximately 15-20% lower, with some as low as $2,200 per infusion.
- Insurance and pharmacy benefit manager negotiations typically reduce patient out-of-pocket costs significantly.
Market Drivers
- Increasing prevalence of autoimmune diseases: Nearly 1% of the global population has rheumatoid arthritis; Crohn's disease affects about 100-200 per 100,000 people.
- Patent expirations and biosimilar entries have begun to impact pricing and market share.
- Expanded approved indications improve market reach, yet pricing pressures persist.
Price Projections
- Short-term (1-3 years): The average transaction price for branded infliximab will decline by approximately 5-8% annually due to biosimilar competition and payer negotiations.
- By 2025, the average price per infusion is expected to decrease to roughly $2,500 - $2,700 assuming current biosimilar market penetration continues.
- Long-term (3-5 years): Price stabilization or a further decline of 3-5% annually, with biosimilars accounting for 50-60% of the infliximab market share in mature markets.
Revenue Impact
- For an annual patient volume exceeding 300,000 in the U.S., with an average of 6 infusions per year, the total market value for infliximab exceeds $4 billion annually.
- Price reductions could translate into a revenue decrease of 20-25% over five years if biosimilar adoption accelerates and pricing continues to decline.
Regulatory and Policy Factors
- The Biologics Price Competition and Innovation Act (BPCIA) facilitates biosimilar entry, with FDA approvals accelerating biosimilar development timelines.
- Recent policies in the U.S. aim to promote biosimilar uptake, including formulary incentives and risk-sharing agreements.
- Legislation like the Inflation Reduction Act offers potential price negotiation mechanisms for Medicare.
Key Takeaways
- The infliximab market faces ongoing price compression driven by biosimilar competition.
- Short-term price declines are projected at 5-8% annually.
- Long-term impacts include increased biosimilar market share and further price stabilization or reduction.
- Revenues will decline proportionally if market share shifts favor biosimilars or alternative therapies expand.
FAQs
1. What factors influence infliximab pricing?
Pricing depends on manufacturing costs, biosimilar competition, payer negotiations, regulatory policies, and market demand.
2. How significant is biosimilar entry in the infliximab market?
Biosimilars hold approximately 35% of the U.S. market as of 2022, with growth expected to continue rapidly.
3. Will branded infliximab maintain its market share?
Branded product will retain premium status with clinical differentiation but will lose market share as biosimilar adoption increases.
4. Are there regional differences in pricing?
Yes, Europe and emerging markets generally have lower prices due to different regulatory and reimbursement frameworks.
5. How might upcoming policies impact infliximab prices?
Policies promoting biosimilar use and price negotiation mechanisms could accelerate price declines.
Sources
- IQVIA, "Biologic and biosimilar market dynamics," 2022.
- FDA, "Biosimilar Development and Approval," 2022.
- EvaluatePharma, "Biologic Market Forecast," 2022.
- Center for Biosimilars, "Market access and pricing," 2022.
- CMS, "Inflation Reduction Act and drug pricing," 2022.
